Description
NOVOSEVEN RT
First action · last action
2010-02-05 · 2010-02-05
Transactions
1
First transaction's obligation
$19,128
Base + all options value (sum of deltas)
$19,128
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797P5828X
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2010-02-05+$19,128= $19,128
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2010-02-05 | +$19,128 | $19,128 | NOVOSEVEN RT |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI W72BJMJYBMN3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79725A0025 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
| 36F79721D0044 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
| 36E79720D0071 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2020 |
| 36E79720D0018 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2020 |
| 36F79719D0181 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2019 |
| VA797P15C0039 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2015 |
Other recipients under 6505 from 635-OKLAHOMA CITY (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25615F0927 | CSL BEHRING L.L.C. | 635-OKLAHOMA CITY | $5,550 | FY2015 |
| VA25613P0086 | ESSENTIAL PHARMACEUTICALS LLC | 635-OKLAHOMA CITY | $4,608 | FY2013 |
| VA25613F0046 | TALECRIS BIOTHERAPEUTICS HOLDINGS CORP. | 635-OKLAHOMA CITY | $19,346 | FY2013 |
| VA25612F2263 | EUSA PHARMA (USA), INC. | 635-OKLAHOMA CITY | $4,362 | FY2012 |
| VA25612F2253 | TALECRIS BIOTHERAPEUTICS HOLDINGS CORP. | 635-OKLAHOMA CITY | $19,344 | FY2012 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA635A00018_3600_V797P5828X_3600 · retrieved 2026-09-26.